Researcher
Hannelore Denys
- Keywords:Clinical trials, Fundamental and translational research, Uterine cancer, cervical cancer, Breast cancer, Ovarian cancer
- Disciplines:Cancer diagnosis, Cancer epidemiology, Oncology not elsewhere classified, Cancer therapy, Cancer biology
Affiliations
- Board of Governors/Executive Board (Administrative office)
Member
From1 Oct 2022 → Today - Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Department of Internal medicine (Department)
Member
From1 Oct 2011 → 30 Sep 2018
Projects
1 - 10 of 11
- Chitinase 3-like 1 as novel immunotherapeutic target in triple-negative breast cancerFrom1 Oct 2021 → TodayFunding: FWO junior postdoctoral fellowship
- PRIMMO trial - Extracellular vesicles to predict response to checkpoint inhibitors in cervical and endometrial cancer patientsFrom1 Jan 2021 → 31 Dec 2021Funding: Nonprofit institution or equivalents
- Analyzing circulating bacterial extracellular vesicles in cancer patients to identify their composition and biomarker potential.From1 Nov 2020 → 31 Mar 2023Funding: FWO fellowships
- Preclinical validation of novel anti-EMT therapy for malignant triple negative breast cancerFrom1 Mar 2020 → TodayFunding: Nonprofit institution or equivalents
- EV-TRACE: Extracellular Vesicle Tracking using surface proteins and Resonance Assays to detect breast Cancer in Early stageFrom1 Jan 2020 → 31 Dec 2023Funding: FWO Strategic Basic Research (SBO)
- Heading towards an in vivo predictive test for personalized ovarian cancer treatment: application of novel therapies in zebrafish patient derived xenograftsFrom1 Nov 2019 → TodayFunding: FWO Strategic Basic Research Grant
- Impact of vaginal morbidity on sexual functioning in cervical cancer patients treated with neo-adjuvant chemotherapy followed by surgery.From1 Jan 2019 → 31 Dec 2020Funding: FWO research project (including WEAVE projects)
- beurs EVDS Sofie Van Dorpe: Extracellular vesicles as blood-based biomarker for early stage ovarian cancerFrom1 Oct 2018 → 30 Sep 2019Funding: Foundations, funds and other with scientific goal
- Targeting cancer-associated fibroblasts to overcome immunosuppressive mechanisms in mismatch repair-deficient tumorsFrom1 Oct 2018 → 30 Sep 2022Funding: FWO fellowships
- Combination of radiotherapy, PD-1 blockade and an immune-modulatory cocktail to combat cervical and uterine cancerFrom1 Jan 2017 → 31 Dec 2021Funding: Foundations, funds and other with scientific goal
Publications
11 - 20 of 125
- Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer : a study of the Belgian and Luxembourg Gynaecological Oncology Group(2022)
Authors: Ignace Vergote, Els Van Nieuwenhuysen, Stefanie De Waele, Christof Vulsteke, Caroline Lamot, Heidi Van den Bulck, Nele Claes, Marie-Pascale Graas, Guy Debrock, Isabelle Spoormans, et al.
Pages: 753 - 760 - Safety of pre- or postoperative accelerated radiotherapy in 5 fractions : a randomized pilot trial(2022)
Authors: Vincent Vakaet, Hans Vanhulle, Ingeborg Hilderson, Eline Naert, Wilfried De Neve, An Hendrix, Menekse GOKER, Herman Depypere, Glenn Vergauwen, Rudy Van den Broecke, et al.
Pages: 10 - 15 - Association of cell death markers with tumor immune cell infiltrates after chemo-radiation in cervical cancer(2022)
Authors: Teodora-Eugenia Oltean, Kelly Lemeire, Marnik Vuylsteke, Hannelore Denys, Peter Vandenabeele, Sandy Adjemian Catani
- 2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial(2022)Volume: 32
Authors: Emiel De Jaeghere, Sandra Tuyaerts, Ann M.T. van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.
Pages: A187 - A188 - Completeness and selection bias of a Belgian multidisciplinary, registration-based study on the EFFectiveness and quality of Endometrial Cancer Treatment (EFFECT)(2022)
Authors: J Vanbraband, N Van Damme, G Bouche, G Silversmit, A De Geyndt, E de Jonge, G Jacomen, F Goffin, Hannelore Denys, F Amant
- Distinct transcriptional programs in ascitic and solid cancer cells induce different responses to chemotherapy in high-grade serous ovarian cancer(2022)
Authors: Nele Loret, Niels Vandamme, Joachim Taminau, Kato De Clercq, Sven Jonckheere, Kelly Lemeire, Sofie De Prijck, Kevin Verstaen, Steven Weyers, Hannelore Denys, et al.
Pages: 1532 - 1547 - Clear cell carcinoma of the endometrium(2022)
Authors: Giorgio Bogani, Isabelle Ray-Coquard, Nicole Concin, Natalie Y.L. Ngoi, Philippe Morice, Takayuki Enomoto, Kazuhiro Takehara, Hannelore Denys, Domenica Lorusso, Robert Coleman, et al.
Pages: 658 - 666 - European experts consensus : BRCA/homologous recombination deficiency testing in first-line ovarian cancer(2022)
Authors: I. Vergote, A. González-Martín, I. Ray-Coquard, P. Harter, N. Colombo, P. Pujol, D. Lorusso, M.R. Mirza, B. Brasiuniene, R. Madry, et al.
Pages: 276 - 287 - A case of corneal melting in a patient with HER2-positive breast cancer(2022)
Authors: Melissa Vereecken, Hannelore Denys, Dimitri Roels
Pages: 1036 - 1041 - Risk of thrombo-embolic events in ovarian cancer : does bevacizumab tilt the scale? A systematic review and meta-analysis(2021)
Authors: Micky Saerens, Emiel De Jaeghere, Nele Vandemaele, Hannelore Denys, Eline Naert